Amylyx Pharmaceuticals, Inc. (AMLX)
Nasdaq: AMLX · Pharmaceutical Preparations · Cambridge, MA · filing with the SEC since 2015
Who owns Amylyx Pharmaceuticals, Inc.
As filed with the SECHolders of 5% or more
5
Fmr LLC holds 15% of COMMON STOCK, as its SCHEDULE 13G/A filed Feb 5, 2026 says.
Directors and officers
10
report now, of 13 people on the record since 2022. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 5 named at left.
Holders of 5% or moreshare of the class, as filed
Fmr LLC
SCHEDULE 13G/A · filed Feb 5, 2026 · COMMON STOCK · 10.7% in Oct 7, 2025
Perceptive Advisors LLC
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, $0.0001 par value per share · 8.2% in Nov 14, 2025
Blackrock, Inc.
SCHEDULE 13G/A · filed Jan 21, 2026 · Common Stock · 5.5% in Jul 17, 2025
TCG Crossover GP II, LLC
SCHEDULE 13G/A · filed Feb 17, 2026 · Common Stock, $0.0001 par value per share
Commodore Capital LP
SCHEDULE 13G · filed Nov 17, 2025 · Common Stock, $0.0001 par value per share
Point72 Asset Management, L.P.
SCHEDULE 13G/A · filed Nov 14, 2025 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 5.3% in Jun 25, 2025
Panacea Venture Healthcare Fund II, L.P.
SCHEDULE 13G/A · filed Feb 14, 2025 · Common Stock, par value $0.0001 per share · reported falling below 5%
Adage Capital Management, L.P.
SCHEDULE 13G/A · filed Feb 12, 2026 · Common Stock, $0.0001 par value per share · reported falling below 5%, from 6.39% in Nov 13, 2025
The Vanguard Group
SCHEDULE 13G/A · filed Mar 26, 2026 · Common Stock · reported falling below 5%, from 5.28% in Jan 30, 2026
What AMLX reports owning in othersstakes of 5% or more, and other ties
5 subsidiaries in 5 countries, from the list filed with the 10-K filed Mar 3, 2026.
Insider tradesForm 4
39sales
2purchases
11sales on a scheduled plan
6people selling
$17.3Msold, in dollars
$200,000bought, in dollars
Open-market trades on Form 4 from Nov 12, 2025 to Nov 12, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 12, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window7 of 25 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Cohen Joshua B | Co-Chief Executive Officer | 9 | $6.6M | 2 | 0 | $0 |
| Klee Justin B. | Co-Chief Executive Officer | 9 | $6.6M | 2 | 0 | $0 |
| Frates James M | Chief Financial Officer | 9 | $1.8M | 4 | 0 | $0 |
| Mazzariello Gina | Chief Legal Officer | 7 | $1.0M | 2 | 0 | $0 |
| Milne George M Jr | director | 1 | $800,000 | 1 | 0 | $0 |
| Bedrosian Camille L | Chief Medical Officer | 4 | $500,000 | 0 | 0 | $0 |
| Firestone Karen | director | 0 | $0 | 0 | 2 | $200,000 |